Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and... see more

TSXV:VPT - Post Discussion

VentriPoint Diagnostics Ltd > Very good news Dr.Adams
View:
Post by jopatclo on Oct 08, 2024 8:52am

Very good news Dr.Adams

Very good news Dr.Adams $$
Dear Friend;
 
Attached is today’s news release, which reports on a number of regulatory audits that the Company has undergone recently to preserve its licenses to sell the VMS+ in Canada, USA, Europe and the UK.  The medial device industry is carefully monitored and guidelines for continuous verification of compliance with regulations have recently updated so everyone selling or developing medical devices has to undergo more stringent audits to re-certify their existing devices.  Venrtipoint has now passed all these audits.  This allows the Company to continue to sell and support VMS+ models being used in leading hospitals in Canada, USA, Europe and the UK as well as to apply for approvals for the latest premium VMS+ model, version 4.0, in Europe and the UK.  The VMS+4.0 has already been licensed for sale by Health Canada and is under review by the US-FDA.  
 
I remind you the Company has four VMS+ models currently being used or sold around thew world:
VMS+3.0 - basic model for semi-automated analysis of all 4 chambers of the heart for patients without electronic heart devices such as pacemakers or defibrillators;
VMS+3.2 - advanced model for semi-automated analysis of all 4 chambers of the heart for all patients including those with electronic heart devices such as pacemakers or defibrillators;
VMS+4.0 - premium model for automated analysis of all 4 chambers of the heart for all patients including those with electronic heart devices such as pacemakers or defibrillators;
QMS - basic model for semi-automated analysis of the right ventricle (RV) of the heart for patients without electronic heart devices such as pacemakers or defibrillators, which is manufactured and sold in China by our partner Yutian.
 
Thank for the support and interest as we continue to improve cardiac diagnostics for everyone, everywhere and especially for children born with heart defects.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities